Connect with us

Cannabis

InnoCan Pharma Enters into Letter of Intent to Develop and Produce Exosomes for Use in its CBD-Loaded Exosome (CLX) Treatments

Newsfile

Published

on

Calgary, Alberta and Tel Aviv, Israel–(Newsfile Corp. – May 22, 2020) – InnoCan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that its wholly-owned subsidiary, Innocan Pharma Ltd. (“Innocan Israel”), has entered into a letter of intent (“LOI”) with Adva Biotechnology Ltd. (“ADVA”) dated May 21, 2020. The LOI sets out the indicative terms of an exosome production and development agreement (the “Exosome Production Agreement”) which the parties intend to negotiate and conclude within 120 days from the date of the LOI. ADVA is an Israeli company that specializes in the development of end-to-end advanced therapy manufacturing solutions.

The Exosome Production Agreement will provide a framework for the production of exosomes and related development services by ADVA. As part of Innocan’s research and development activities with the Tel Aviv University led by Prof. Daniel Offen, Innocan intends to load the produced exosomes with CBD (“CLX”) to be used towards its efforts to develop a treatment for COVID-19 and additional central nervous system indications.

The services to be provided by ADVA will be provided in three stages:

  • Stage 1: pilot study involving producing exosomes from 4 to 6 production runs according to the specifications of Innocan, expected to be completed in 6 to 8 weeks.
  • Stage 2: production of exosomes from 4 to 5 different donors, conducting comparable tests, production process optimization and characterization of the final exosome product.
  • Stage 3: upscaling the finalized exosome product for commercial production.

Pursuant to the LOI, the requirement to complete Stage 1 of the services is immediately binding on the parties. Innocan is required to make certain payments to ADVA: (i) within 5 days following the signing of the LOI, and (ii) upon the successful completion of Stage 1. The immediate impact of the LOI is that ADVA will commence production of the exosomes, thereby accelerating the research and development of CLX prior to entering into the Exosome Production Agreement.

Iris Bincovich, CEO of Innocan, stated: “we are looking forward to working with the ADVA team, a team that brings experience of many years in development of bioreactors at the highest level of mesenchymal stem cell production in various companies. The uniqueness of the mesenchymal stem cell production unit to be developed by ADVA under the LOI and the Exosome Production Agreement is expected to provide Innocan with full control of many important parameters of the exosome production process, allowing Innocan and Prof. Offen’s team to optimize the exosome and production system.”

Dr. Ohad Karnieli, ADVA founder and CEO stated: “we are very pleased to collaborate with Innocan and Prof. Offen’s team on the CLX project. Our technology is an excellent fit to Innocan’s needs and the ability of having full control and high flexibility at the production process may lead to better, faster and high yield production of the exosomes and cells.”

About Adva Biotechnology Ltd.

ADVA is an Israeli based private company focused on developing technologies for cell therapy manufacturing. ADVA developed an automated, controlled and simple to use platform for cell manufacturing – initially for immune cell therapies (ICT) such as Chimeric Antigen Receptor (CAR T), T Cell Receptor (TCR), Natural Killer cells (NK) and T infiltrating Lymphocytes (TIL’s). The automated platform is designed to allow autologous manufacturing of additional types of cells with a change in the disposable chamber allowing efficiency and flexibility with a long pipeline of products.

About Innocan Pharma Corporation

The Company, through its wholly-owned subsidiary, Innocan Israel, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”) with other pharmaceutical ingredients. Innocan and Ramot at Tel Aviv University are collaborating on the development of a new exosome-based technology that targets both central nervous system indications and the COVID-19 Coronavirus. The Company believes that CBD-loaded exosomes may hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. The Company, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, plans to test the liposome platform on several potential indications. The Company is also working on a dermal product integrating CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of InnoCan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For InnoCan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including the entering into of the Exosome Production Agreement within the time frames set out in the LOI or at all, the exosomes produced under the Exosome Production Agreement being successfully loaded with CBD and/or successfully deployed towards the treatments of COVID-19 or other indications, expectations and assumptions concerning the anticipated benefits of the product markets, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan Pharma does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/56368

Cannabis

MediPharm Labs and Ace Valley Deliver Innovative Vapes – Now Available in Several Markets Across Canada

GlobeNewswire

Published

on

TORONTO, May 25, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that its highly anticipated and innovative suite of “Ace Valley Vapes” are officially available in several markets across Canada.   The Company shipped three new vape products under this white label brand-line to multiple provinces last week.
The launch of the Ace Valley Vapes is the culmination of the Company’s previously announced white label agreement through its subsidiary, MediPharm Labs Inc., with AV Cannabis Inc. (d/b/a Ace Valley). Through this collaboration, Ace Valley leveraged its leading brand traction and product strategy expertise to design, brand and market new and innovative vaporizer products, while MediPharm Labs provided raw material from its supply chain, high-quality cannabis distillate, formulation and filling expertise from its GMP-certified facility, as well as distribution services across Canada to cannabis distributors and retailers.“Ace Valley has emerged as one of Canada’s true cannabis brands. We are proud to be partnering with a team that consistently raises the bar through product development and marketing ingenuity, further elevated by our superiour product formulations and top CPG-quality processes,” said Pat McCutcheon, Chief Executive Officer of MediPharm Labs.“We are passionately building a great cannabis brand in Canada,” said Mike Wagman, Chief Executive Officer of Ace Valley. “Our new all-in-one vapes, with an innovative logo light-up feature, are a big part of our platform and we have a strong partner in MediPharm Labs, the leader in cannabis extraction and purified cannabis concentrates in Canada.”Unique Product Formulations with Original Vape Hardware
Each Ace Valley Vape is an all-in-one unit with 0.3 ml of formulated cannabis distillate. Working in collaboration with Ace Valley, MediPharm Labs’ Applied Science team formulated three unique products – CBD, Sativa and Indica options – each comprised of 95% distillate and 5% botanically derived terpenes, with zero carrier oil, other additives, or thickening agents. Ace Valley selected this variety of vape options so consumers can curate their experience.
The vape hardware is an all-in-one unit, not requiring a separate purchase of battery and vapourizer cartridge. Ace Valley wanted to offer customers something convenient, consistent, and easy-to-use.  By providing an integrated all-in-one hardware device, they were able to deliver maximum consistency from one experience to the next, as the distillate and vapourizing hardware have been specifically designed and tested together.“The concept for our new vapes is the brainchild of our co-founder, Noah Gill, who wanted customers to have a fun way to experience the device,” explained Mike Wagman, CEO of Ace Valley. “Unlike other vape pens on the market, the Ace Valley Vape lights up each of the four colour bands in our logo sequentially as you inhale. This provides the customer with simple and intuitive control and a unique interaction.”Multi-Province Distribution
MediPharm Labs has already completed shipments to Ontario, BC and Alberta distribution hubs.
The Ace Valley Vapes are anticipated to be available at select retailers in ON, BC, Alberta, Manitoba, and Saskatchewan.
About Ace Valley
Ace Valley is a leading recreational cannabis brand.  Since launching in October 2018, Ace Valley has built a curated, ready-to-use portfolio of pre-rolls, vapes and real-fruit gummies* (*launching soon) with wholesale and retail distribution across most of Canada.  Ace Valley drives leading sales and brand awareness by leveraging its product strategy expertise, consumer insights and loyal community of fans.
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, they formulate, consumer-test, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.
For further information, please contact:
Laura Lepore, VP, Investor Relations
Telephone: +1 416.913.7425 ext. 1525
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, expected sale of the Ace Valley Vapes at various provincial retailers. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
All information contained in this press release with respect to Ave Valley was supplied by Ace Valley for inclusion herein.Photos accompanying this announcement are available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/e0e9a2f1-456e-4d74-9b83-ed4292c56ea0https://www.globenewswire.com/NewsRoom/AttachmentNg/2795c368-8023-462a-a7ee-94d0418c39d1

Continue Reading

Cannabis

GreenStar Biosciences Announces Stock Option Issuance and Cancellation of Stock Options

Newsfile

Published

on

Vancouver, British Columbia–(Newsfile Corp. – May 25, 2020) – GreenStar Biosciences Corp. (CSE: GSTR) (“GreenStar” or the “Company”), announces it has granted stock options to acquire a total of 200,000 common shares of the Company to a director of the Company. The options are exercisable at a price of $0.14 per share and expire three years from the date of grant. The options are subject to various vesting provisions where 150,000 of the options granted vest immediately on the grant date, 7,143 options vest monthly from June 30, 2020 to November 30, 2020 and 7,142 options vest on December 31, 2020.

The Company also announces the cancellation of a total of 150,000 previously granted stock options made to a former director.

About GreenStar

GreenStar is a growth-oriented technology and services company that provides real estate, financial, management, IP and branding support to licensed cannabis businesses in the United States. GreenStar operates a growing portfolio of tenant partner companies in the United States. GreenStar applies refined strategies tested in the Washington State market to help partner companies reach their full potential. Based in Vancouver, BC, GreenStar intends to facilitate growth through acquisitions and development of additional assets, products and technologies in legal cannabis markets by leveraging its capital markets, branding and operational expertise.

For further information please contact:

GreenStar Biosciences Corp.
Tom Baird, CEO
info@greenstarbiosciences.com
Telephone: (604) 834-9499

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/56479

Continue Reading

Cannabis

Matica Announces Delayed Filing of Interim Financial Statements Pursuant to OSC Blanket Instrument 51-502

Newsfile

Published

on

Toronto, Ontario–(Newsfile Corp. – May 22, 2020) – Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTCQB: MMJFF) (“Matica” or the “Company”) today announced that it will be delaying the filing and delivery of certain of its continuous disclosure documents, in accordance with Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Finance Requirements of the Ontario Securities Commission (the “Blanket Exemption Order”) which was adopted for the purpose of providing certain filing and other relief to issuers in light of the challenges posted by the COVID-19 pandemic.

The Company is relying on the Blanket Exemption Order in delaying the Company’s interim financial statements for the three month period ended March 31, 2020 and related certifications; and the Company’s management discussion and analysis for the three month period ended March 31, 2020.

The officers and directors of the Company and certain other persons will remain subject to a trading black-out pursuant to which such persons are prohibited from trading in any securities of the Company until the end of the second full trading day following the day on which the Required Annual Filings are filed on SEDAR and a corresponding news release is issued by the Company.

The Company currently intends to make the required interim filings by July 15, 2020.

About Matica

Matica is a multi-faceted, innovative company in the Quebec cannabis space. Its subsidiary, RoyalMax Biotechnology Canada Inc. is a Dorval, Quebec based Health Canada Licence Holder. RoyalMax has been granted a standard cultivation licence, standard processing and medical sales licences by Health Canada.

For more information on Matica Enterprises please visit the website at: www.maticaenterprises.com.

On behalf of the Board of Directors
MATICA ENTERPRISES INC.
Boris Ziger
Boris Ziger, CEO & Chairman

The Company’s public filings are available for review at www.sedar.com and www.thecse.com.

For further information, please contact Boris Ziger, at:
Telephone: 416-304-9935
E-mail:
info@maticaenterprises.com
Website: www.maticaenterprises.com , www.maticammj.com

Disclaimer for Forward-Looking Information

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

This news release contains statements about the Company’s information that may be made available on the S&P Capital IQ Corporation Records Listing Program and the business of Matica that are forward-looking in nature and as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/56423

Continue Reading

Trending Online

Grassnews is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Grassnews digests / hand picks the latest news about the CBD / Legal Cannabis industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Grassnews .com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania